750,000 Shares in ALX Oncology Holdings Inc. $ALXO Bought by Nantahala Capital Management LLC

Nantahala Capital Management LLC acquired a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 750,000 shares of the company’s stock, valued at approximately $1,552,500.

A number of other institutional investors also recently bought and sold shares of the company. Beacon Pointe Advisors LLC purchased a new position in ALX Oncology in the second quarter worth about $26,000. Callan Family Office LLC purchased a new stake in shares of ALX Oncology during the 2nd quarter valued at about $46,000. Invesco Ltd. purchased a new stake in shares of ALX Oncology during the 1st quarter valued at about $46,000. The Manufacturers Life Insurance Company bought a new position in shares of ALX Oncology in the 2nd quarter worth approximately $64,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of ALX Oncology in the 3rd quarter worth approximately $66,000. Institutional investors own 97.97% of the company’s stock.

Wall Street Analyst Weigh In

ALXO has been the subject of several recent research reports. Weiss Ratings upgraded shares of ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. Wall Street Zen upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $4.60.

ALX Oncology Stock Performance

NASDAQ:ALXO opened at $2.00 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71. The stock has a 50-day simple moving average of $2.01 and a two-hundred day simple moving average of $1.97. The firm has a market capitalization of $276.56 million, a PE ratio of -1.77 and a beta of 0.42. ALX Oncology Holdings Inc. has a 52-week low of $0.96 and a 52-week high of $2.66.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. Analysts forecast that ALX Oncology Holdings Inc. will post -0.6 EPS for the current year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.